According to Iconovo, the European Patent Office has indicated that it will approve a patent application for an additional patent that will provide protection for Iconovo’s ICOres reservoir-based dry powder inhaler platform until 2038. ICOres is already covered by patents in a number of countries, including Japan, China, and the US.
Iconovo CEO Johan Wäborg commented, “The preliminary notification from the European Patent Office strengthens our intellectual property rights for ICOres in the EU and thereby increases the value of our product portfolio. The first ICOres product expected to be launched in the EU is based on the drugs budesonide and formoterol and is being developed by our partner Amneal as a generic version of the bestseller Symbicort Turbuhaler. Amneal’s latest pharmacokinetic pilot study indicates that the product’s properties would enable the achievement of the criteria for bioequivalence in a pivotal study, and we look forward to this important step on the road to a potential market launch.”
Read the Iconovo press release
